Biotech StocksInsights Cowen Maintains Outperform On Intercept Following Business Update Cowen analyst Ritu Baral maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $420, as the company provided a clinical update … Jason Cohen, January 15, 2015
Biotech StocksInsightsTop-Rated Analysts Wedbush Maintains Outperform On Intercept Pharmaceuticals Following PBC Supergroup Meta-Analysis Publication In a research report issued December 7, 2014, Wedbush analyst Liana Moussatos maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT), as the company announced … Ben Mahaney, Editor, December 9, 2014
Analyst InsightsBiotech StocksExclusively PublishedInsightsMost PopularTop-Rated Analysts Oppenheimer Comments On Intercept As FLINT Manuscript Has Been Accepted For Publication In A Journal Oppenheimer analyst Akiva Felt maintained an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), as a webpage from Johns Hopkins School of Public Health states that … Ben Mahaney, Editor, November 4, 2014
Biotech StocksInsights Deutsche Bank Reiterates Buy On Intercept Pharmaceuticals, $500 PT In a research report issued today, Deutsche Bank analyst Alethia Young reiterated a Buy rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a price target … Corey Williams, October 22, 2014
